ARMP
AMEXArmata Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Website
News25/Ratings0
News · 26 weeks31-94%
2025-10-262026-04-19
Mix2190d
- Insider11(52%)
- SEC Filings6(29%)
- Other4(19%)
Latest news
25 items- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- SECSEC Form 10-K filed by Armata Pharmaceuticals Inc.10-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- PRArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial ResultsLOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and full-year ended December 31, 2025. Fourth Quarter 2025 Financial ResultsGrant Revenue. The Company recognized grant revenue of $1.1 million for the three months ended December 31, 2025 as com
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- PRArmata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate UpdateLOS ANGELES, March 19, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it will delay the announcement of its financial results for its fourth quarter and full-year ended December 31, 2025, and provided a corporate update. The Company requires additional time to complete its financial reporting and ant
- INSIDERChief Business Officer Kyme Pierre covered exercise/tax liability with 1,030 shares, decreasing direct ownership by 10% to 9,461 units (SEC Form 4)4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERChief Executive Officer Birx Deborah covered exercise/tax liability with 4,919 shares, decreasing direct ownership by 2% to 212,458 units (SEC Form 4)4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERSEC Form 4 filed by Director Kramer Robin4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERSEC Form 4 filed by Chief Business Officer Kyme Pierre4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERSEC Form 4 filed by SVP, Finance, and PFO House David Duane4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERSEC Form 4 filed by Director Patti Joseph M4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERSEC Form 4 filed by Director Peterson Todd C.4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERSEC Form 4 filed by Director Odysseas Kostas D4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Birx Deborah4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERSEC Form 4 filed by Director Schlesinger Sarah J.4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERSEC Form 4 filed by Director Haimovitz Jules4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- PRArmata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus QIDP Designation provides for five years of market exclusivity and the potential for fast track and priority reviewLOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the "FDA") has granted AP-SA02, the Company's Staphylococcus aureus ("S. aureus") multi
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Armata Pharmaceuticals Inc.SCHEDULE 13D/A - Armata Pharmaceuticals, Inc. (0000921114) (Subject)
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- PR/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./In the news release, Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus, issued Jan. 13, 2026 by Armata Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the original version contained incorrect information introduced by PR Newswire during transmission. The complete, corrected release follows, with additional details at the end: Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia FDA agreed that data from the Phase 2a diSArm st
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- PRArmata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureusFDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3study First bacteriophage company to advance a clinical candidate to Phase 3 LOS ANGELES, Jan. 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced the conclusion of an End-of-Phase 2 ("EOP2") written response from the U.S. Food and Drug Administration ("FDA") and plans to advance the Company's intravenously-administered Stap
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)